Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03685201 · ClinicalTrials.gov registry record · NA
Postprandial Glycemia in Orange Products
A NA study, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT03685201: Completed NA study, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
NCT03685201 is a NA study that has completed, run by Clinical Nutrition Research Center, Illinois Institute of Technology. The registered enrollment target is 43 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03685201, a NA study, has completed, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
The primary objective of the study is to compare the effects of a whole orange, orange juice alone, and orange juice with pomace on 2 hr glycemic response as measured by maximal glucose concentration.
Primary Outcome
Plasma Glucose maximal concentration (Cmax) over 2 hours
Interventions
- DIETARY_SUPPLEMENT Orange Juice1
- DIETARY_SUPPLEMENT Orange Juice2
- DIETARY_SUPPLEMENT Raw Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-09-13 |
| Est. Completion | 2019-11-24 |
| Phase | NA |
What the finished NCT03685201 record still lists
NCT03685201 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Orange Juice1 is the first listed.
NCT03685201 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03685201 about?
NCT03685201 is a clinical study titled "Postprandial Glycemia in Orange Products". The primary objective of the study is to compare the effects of a whole orange, orange juice alone, and orange juice with pomace on 2 hr glycemic response as measured by maximal glucose concentration.
What is the current status of trial NCT03685201?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2018-09-13. Estimated completion is 2019-11-24.
What interventions are being tested in trial NCT03685201?
The interventions under investigation include: Orange Juice1 (DIETARY_SUPPLEMENT), Orange Juice2 (DIETARY_SUPPLEMENT), Raw Orange (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03685201?
This trial is sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03685201's enrollment target sits among peer trials
43 1435th of 2000 higher than 565 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI